Effectiveness of steroid treatment in myasthenia gravis: a retrospective study

Cosi, V.; Citterio, A.; Lombardi, M.; Piccolo, G.; Romani, Alfredo; Erbetta, Alessandra

doi:10.1111/j.1600-0404.1991.tb04899.x

Cited by 43 publications

(22 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…112 Favorable outcomes from prednisone therapy correlated with increasing age. 23,112 Besides slowness of improvement onset, alternate-day prednisone may result in less final overall benefit than with daily high doses, 138 but also in greatly reduced incidence of undesirable side effects.…”

Section: Long-term Immunological Treatmentsmentioning

confidence: 97%

Clinical evaluation and management of myasthenia gravis

2004

View full text Add to dashboard Cite

Myasthenia gravis (MG) is a syndrome of fluctuating skeletal muscle weakness that worsens with use and improves with rest. Eye, facial, oropharyngeal, axial, and limb muscles may be involved in varying combinations and degrees of severity. Its etiology is heterogeneous, divided initially between those rare congenital myasthenic syndromes, which are genetic, and the bulk of MG, which is acquired and autoimmune. The autoimmune conditions are divided in turn between those that possess measurable serum acetylcholine receptor (AChR) antibodies and a smaller group that does not. The latter group includes those MG patients who have serum antibodies to muscle-specific tyrosine kinase (MuSK). Therapeutic considerations differ for early-onset MG, late-onset MG, and MG associated with the presence of a thymoma. Most MG patients can be treated effectively, but there is still a need for more specific immunological approaches.

show abstract

Section: Long-term Immunological Treatmentsmentioning

confidence: 97%

Clinical evaluation and management of myasthenia gravis

2004

View full text Add to dashboard Cite

show abstract

“…Steroid drugs are first-line drugs for immunomodulatory therapy in MG patients [57,64], and their effectiveness has been clarified [65][66][67]. Together with anticholinesterase drugs, steroids are often administered before surgery.…”

Section: Steroid Drugsmentioning

confidence: 99%

“…In general, one course comprising intravenous infusion of methylprednisolone at 1000 mg/day for 3 days is usually conducted for 1-3 courses [90][91][92]. Although the long-term effects are unknown [65], it has been reported that, even after thymectomy without MG crisis, steroid pulse therapy may be able to reduce the doses of subsequent oral steroids [93]. A placebo double-blind study demonstrated the efficacy of steroid pulse therapy, with an efficacy rate of 80 % and a mean duration of effect of 8 weeks (4-14 weeks) [91].…”

Section: Steroid Pulse Therapymentioning

confidence: 99%

Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014

Kadota

Horio

Mori

et al. 2015

Gen Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Thymectomy is regarded as a useful therapeutic option for myasthenia gravis (MG), though perioperative management in MG patients is largely empirical. While evidence-based medicine is limited in the perioperative management of MG patients, treatment guidelines are required as a benchmark. We selected issues faced by physicians in clinical practice in the perioperative management of extended thymectomy for MG, and examined them with a review of the literature. The present guidelines have reached the stage of consensus within the Japanese Association for Chest Surgery.

show abstract

“…GCs, such as prednisone, are a long-term therapeutic approach for MG and have been shown to reduce the number of circulating lymphocytes in serum to achieve improvement or remission of disease in the majority (approx. 75%) of patients [43][44][45] . In ocular MG, evidence suggests that GC treatment may delay or stop the progression to other classes of MG.…”

Section: Anti-inflammatory Therapiesmentioning

confidence: 99%

Intercommunication between the Neuroendocrine and Immune Systems: Focus on Myasthenia Gravis

Mays

Butts

2011

Neuroimmunomodulation

View full text Add to dashboard Cite

Crosstalk exists between the nervous, endocrine, and immune systems, and perturbations in these interactions have been associated with disease. This includes production of neuroendocrine factors that alter immune system activity and increase susceptibility to or severity of immune-related conditions, such as myasthenia gravis (MG) – a T-cell-dependent, B-cell-mediated autoimmune disorder. MG results from impairment of transmission to the neuromuscular junction and involves the thymus – especially in early-onset disease, but the exact mechanism by which the thymus impacts disease is unclear. MG afflicts millions of individuals worldwide each year, and both men and women can develop symptoms. However, prevalence and age of onset differs between men and women. Women exhibit higher incidence and earlier age of onset compared to men, and disease fluctuates during pregnancy. This suggests that sex hormones play a role in influencing disease outcome. In this review, we will consider what is known about the manifestation of MG, theories on how different forms of MG are influenced or alleviated by steroid hormones, current treatment options, and what measures could be important to consider in the future.

show abstract

Effectiveness of steroid treatment in myasthenia gravis: a retrospective study

Cited by 43 publications

References 4 publications

Clinical evaluation and management of myasthenia gravis

Clinical evaluation and management of myasthenia gravis

Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014

Intercommunication between the Neuroendocrine and Immune Systems: Focus on Myasthenia Gravis

Contact Info

Product

Resources

About